Nortran Pharmaceuticals Inc. and Hoechst Marion Roussel announce collaborativeagreement

Vancouver, Canada -- Nortran Pharmaceuticals Inc., the Canadian drug discovery company, and Hoechst Marion Roussel ("Hoechst"), the global pharmaceutical subsidiary of Hoechst AG, today announced the signing of a collaborative agreement in the area of cardiac arrhythmias. This collaboration will capitalize on the complementary expertise of the two companies in this area.

Under the terms of the agreement Nortran and Hoechst Marion Roussel will test investigational antiarrhythmic compounds developed by both companies. The companies will evaluate the pharmacological profiles of their compounds through the use of both companies' proprietary electrophysiological models and other preclinical tests.

"We are delighted to be working with a company of Hoechst Marion Roussel's calibre who have demonstrated their leadership in the field of cardiovascular therapeutics," commented Bob Rieder, President and Chief Executive Officer of Nortran. "We are confident that this agreement will give fresh impetus to the field of antiarrhythmic drugs and create new opportunities that will benefit both the pharmaceutical industry and ultimately patients with the condition."

Nortran recently presented findings of its preclinical research on atrial fibrillation at the European Congress of Pharmacology in Budapest. "The drugs we have developed exhibit unique pharmacological properties which may lead to a new class of antiarrhythmic drug, " said Greg Beatch, Vice President Research, Nortran. "The heart rate dependent activity of our molecules is the basis for safe, effective antiarrhythmic drugs. We are very excited about the potential for our new class of antiarrhythmics. Our collaboration with Hoechst Marion Roussel can only expedite our research program."

Hoechst Marion Roussel, a world leader in pharmaceutical-based health care, is dedicated to extending human life and enhancing its quality through the discovery, development, manufacture and sale of pharmaceutical produ

Contact: Asa Zanatta
Contemporary Communications

Page: 1 2

Related medicine news :

1. Eyetech Pharmaceuticals, Inc. announces macugen data on treating macular degeneration
2. MetaPhore Pharmaceuticals initiates Phase I clinical trial of enzyme mimetic compound for oncology
3. Maret Pharmaceuticals presents promising Phase I/II clinical MARstem™ results at international symposium on new drugs in cancer therapy
4. NIH awards grant to MetaPhore Pharmaceuticals to study novel pain treatments
5. Aventis Pharmaceuticals Allegra (Fexofenadine Hcl) 30-Mg tablets now available to treat seasonal allergies, chronic hives in children 6 to 11 years
6. Pharmaceuticals and personal care products
7. Signal Pharmaceuticals Announces Positive Results In Preclinical Study Of Novel Drug Leads For Treatment Of Osteoporosis
8. Beyond Pharmaceuticals: Business And Academic Leaders Forecast The Future Of "Combinatorial Chemistry"
9. ONYX Pharmaceuticals Reports Phase II Clinical Trial Results At ASCO Meeting
10. The Gerontological Society of America announces Hartford Fellowship recipients
11. TB Alliance announces new drug discovery program with GlaxoSmithKline

Post Your Comments:

(Date:2/19/2019)... ... February 19, 2019 , ... ... provider of advanced delivery technologies and development solutions for drugs, biologics and ... Biologics, will present at the annual US Bioassay Conference of the BioPharmaceutical ...
(Date:2/19/2019)... , ... February 19, 2019 , ... Hospice of Westchester ... Foundation. The funds will support the heart of its operation, the organization’s Home Care ... many years, and we are grateful for their ongoing generosity,” said Mary K. Spengler, ...
(Date:2/19/2019)... (PRWEB) , ... February 19, 2019 , ... ... and communication services, launched their newest release of their enrollment kit solution, called ... order enrollment materials for their new and existing customers. ONEkit is integrated with ...
(Date:2/19/2019)... ... February 19, 2019 , ... According to a recent ... into their previous work and daily routines; and only 26% of widows return to ... The loss of a spouse is one of the most tragic events that one ...
(Date:2/19/2019)... ARBOR, Mich. (PRWEB) , ... February 19, 2019 , ... ... , the genomic search company, announced today that they have entered into a partnership ... , Diploid provides the most efficient workflow for rare disease diagnostics. Moon allows its ...
Breaking Medicine News(10 mins):
(Date:2/19/2019)... ... February 19, 2019 , ... Dr. Jacqueline Subka, a trusted and ... California, to make an appointment at her Simi Valley office to discuss candidacy for ... they can last 20 years or longer with proper care and restore aesthetics and ...
(Date:2/19/2019)... ... 19, 2019 , ... American Mosquito Control Association (AMCA) volunteers ... grade at the school by conducting hands-on science experiments and activities. Topics include ... emphasis on what students can do to protect themselves from mosquito bites and ...
(Date:2/19/2019)... PARK, Kan. (PRWEB) , ... February 19, 2019 , ... ... leader among products designed to treat and prevent Lice. , Lice outbreaks are surprisingly ... each other. Despite popular belief, having head lice is not a sign of uncleanliness; ...
Breaking Medicine Technology:
Cached News: